Challenges, Recommendation Updates in Screening for MASH/MASLD

EP: 1.Understanding NASH/NAFLD vs MASH/MASLD

Now Viewing

EP: 2.Challenges, Recommendation Updates in Screening for MASH/MASLD

EP: 3.Understanding Resmetirom's Potential Based on MAESTRO-NASH

EP: 4.Real-World MASH Populations Compared to MAESTRO-NASH

EP: 5. How New Therapies Change Discussions Around Screening, Management of MASH

This portion of our 5-part peer-to-peer discussion focuses on optimal screening practices for MASH. The conversation delves into the challenges of recognizing and diagnosing MASH, with Arab emphasizing the need to screen high-risk patients due to the nonspecific symptoms of the disease. He suggests targeting populations with known high prevalence rates, such as those with diabetes, obesity, metabolic syndrome, or other metabolic dysfunctions, as they are more likely to develop and progress to advanced liver disease.

Following up on Arab’s statements, Banerjee adds to the discussion by highlighting the association between MAFLD and cardiovascular outcomes, citing research that suggests liver CT can predict cardiovascular risk. He notes regional differences in MAFLD prevalence, with higher rates observed in certain populations, such as those in South America with specific genetic polymorphisms. Both doctors emphasize the importance of tailoring screening and intervention strategies to high-risk populations while making diagnostics more accessible and less reliant on invasive procedures like biopsies.

Editor’s Note: This conversation was recorded on March 14, 2024 prior to the FDA’s approval of resmetirom.

Arab has no relevant disclosures to report. Banerjee’s disclosures include Perspectum Ltd.